Consumer reported complaint for high blood glucose test results.Son is calling on behalf of the customer.The customer is concerned with test results from results obtained of 238, 156, 105, 195 and 168 mg/dl.The customer does not know their expected blood glucose test result range.The customer feels well and did not report any symptoms.Past medical attention was reported; son stated that on (b)(6) 2022 customer had fainted and ems had been called.Customer was transported to the hospital where her blood glucose test result had been 18 mg/dl (fasting/non-fasting was not disclosed).The diagnosis was hypoglycemia; the medical treatment customer received was not disclosed.Customer remained in the er for six hours and then had been discharged; customer's blood glucose test result upon discharge was not disclosed.Customer had followed-up with her primary care physician.At that time, customer was taking tradjenta, glimepiride and glipizide.Customer's primary care physician had discontinued the glimepiride and the glipizide, but found that her blood glucose levels were ranging in the 200's, so the glipizide had been reinstated.During the call, a back to back blood test was not performed by the customer.The product is not stored according to specification (kitchen).The test strip lot manufacturer¿s expiration date is 03/29/2023 and open vial date is was not disclosed.The customer did not have another vial of test strips that had been stored and handled correctly.The meter memory was reviewed for previous test result history: (b)(6).
|
Sections with additional information as of 03-may-2022: h6: updated fda's type of investigation, investigation findings, and investigation conclusions.H10: retention testing was performed using test strips from the same lot.Retention strips tested passed within specifications.
|